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lower turnover, and lower absenteeism associated with adalimumab use. Em-
ployer savings from adalimumab use varies across industries in Brazil. High-wage
sectors, such as the petroleum industry, have both larger absolute costs associated
with RA and larger absolute savings from adalimumab use than do low-wage sec-
tors, such as waste treatment.
Neurological Disorders – Cost Studies
PND3
ESTIMACIÓN DEL PROCESO DE PROCURACIÓN DE ÓRGANOS DE PACIENTES
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OBJECTIVOS: Estimar el costo del proceso de procuración de órganos de pacientes
con muerte cerebral dentro de las instituciones públicas del Sector Salud en México
para identificar los costos en que incurren los hospitales involucrados (donador y
receptor). Lo anterior debido a que el Centro Nacional de Trasplantes (CENATRA) ha
identificado que la falta de incentivos económicos para los hospitales donadores,
disminuye la posibilidad de obtener órganos de aquéllos pacientes que presentan
muerte cerebral. METODOLOGÍAS: El costo del proceso de procuración de órganos
se estimó tomando como referencia el protocolo técnico del CENATRA de México.
Los costos de baterías de laboratorio, de gabinete y de operación durante el proceso
se obtuvieron de fuentes de información tanto de instituciones públicas del Sector
Salud, como de empresas privadas proveedoras de servicios al Sector. Los supues-
tos básicos son: todas las actividades del proceso se enfocan a una procuración
multiórganica (6 órganos) y que el tiempo estimado del proceso es de 36 horas.
RESULTADOS: El costo total del proceso de procuración multiorgánica es de
$47,572.50 pesos mexicanos (PM). Por órgano el costo es de $7928 PM, del cual el
77.67% es incurrido por el hospital donador ($6159 PM), mientras que el 22.33%
restante por el hospital receptor ($1770 PM). Los rubros que implican más del 80%
del costo del proceso son el día terapia intensiva y de hospitalización (59.65%),
mientras que el 22.15% es representado por el gasto en viáticos y alimentación para
el personal médico necesario dentro del proceso. CONCLUSIONES: Los resultados
permiten identificar los costos en que incurre cada una de las partes que inter-
vienen dentro del proceso de procuración de órganos, a considerarse en la imple-
mentación de políticas públicas que incentiven el proceso a nivel nacional.
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OBJECTIVOS: Estimar los costos directos de atención médica de la enfermedad
vascular cerebral (EVC) atribuidos al tabaquismo en un centro neurológico de tercer
nivel. METODOLOGÍAS: Se estimaron los costos de salud directos por ictus atri-
buidos al tabaquismo en 297 pacientes atendidos en el Instituto Nacional de Neu-
rología y Neurocirugía (INNN) en 2009. Metodología: Cost of Illness y microcosteo.
Perspectiva de costeo: proveedor. La utilización se estimó con base en los procedi-
mientos médicos registrados en el expediente clínico. Se utilizó la fracción atri-
buible al tabaco de la EVC para estimar los costos del tabaquismo. Los costos están
expresados en pesos mexicanos ($) y en dólares americanos (USD) del 2009.
RESULTADOS: El costo total de la EVC atribuible al tabaco durante el 2009 fue de
$13,995,388.8 (1,071,123.2 USD). La hemorragia subaracnoidea fue la más costosa. El
costo promedio anual por paciente relacionado con el tabaquismo de las hemorra-
gias intracerebral y subaracnoidea fue, respectivamente, $35,396.2 (2,709.2 USD) y
$66,890.5 (5,119.5 USD). El costo promedio anual asociado al tabaquismo de la EVC
de un paciente en el INNN fue de $45,242.6 (3,462.6 USD). CONCLUSIONES: Este es
el primer estudio que evalúa y confirma los altos costos directos de la atención
médica de los pacientes con EVC atribuidos al tabaco. Si de los 297 pacientes aten-
didos en el INNN durante 2009, 149 no hubieran fumado, el Instituto podría haber
asignado en su mejor uso alternativo los $13,995,188.8 (1,071,123.2 USD). La met-
odología empleada nos provee un gran nivel de especificidad de los datos relacio-
nados con los servicios médicos y financieros utilizados por el paciente con EVC
durante el año analizado.
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OBJECTIVES: The workload of the initial phases of the process of developing a
systematic review (SR) is often underestimated. The screening and quality assess-
ment of studies, usually done by pairs of independent reviewers, is not only time-
consuming, but it also is complicated, tiresome, and prone to mistakes. A comput-
er-software designed to cope with the initial phases of a SR would be of great help.
There is a generalized lack of development in this regard, and the available options
are not very accessible or affordable. The objective of this study is to show the
advances in the development of EROS (Early Review Organizing Software), a web-
based software for the initial phases of a SR process. METHODS: We developed an
online software that helps in performing the first stages of a SR: importation of
citation from a reference manager software or directly after a search in several
medical electronic databases (PubMed, EMBASE, LILACS, etc), screening by title/
abstract, first agreement, uploading of full-text, screening by full-text (tracking
exclusion reasons), quality assessment (second and third agreement respectively),
and distribution of full-text for data collection. RESULTS: EROS is currently being
used in the simultaneous conduction of more than 20 systematic reviews. Its main
characteristics are: a) ability to manage multiple projects; b) differentiation of roles
assigned to reviewers, administrators and librarians; c) multi-language environ-
ment in each review; d) adequate, equitable and timely delivery of full-texts for
evaluation and data abstraction; e) real-time tracking of the whole process for each
role; f) building the study flowchart; g) possibility to work simultaneously in differ-
ent SR’s stages; and h) configurable inclusion/exclusion criteria and other relevant
features. CONCLUSIONS: A computerized SR tool in the initial phases like EROS
saves time, reduces workload for each involved role, and probably enhances SR’s
methodological quality.
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OBJECTIVES: To assess comorbidity patterns among 25 comorbidity candidates in
the Health-related Quality of Life Comorbidity Index. METHODS: Using the
MarketScanTM Medicaid database from 2003 to 2007, type 2 diabetes patients were
targeted. Patterns of comorbidities were analyzed via confirmatory factor analyses
for four subgroups: male, female, black and white. Three models were compared: a
uni-dimensional model, a 2-dimensional model in which 15 and 10 disorders rep-
resented physical and mental domains of comorbidities, respectively, a multi-di-
mensional model in which the dimensions were formed based on tetrachoric cor-
relation matrices. Predictive performances of three comorbidity structures were
assessed using regression analyses for four types of outcomes: physician adher-
ence to diabetes care guideline, patient adherence to oral antidiabetic medication,
health care utilization and costs. The STATA™ and LISREL™ software were
utilized. RESULTS: 9,830 patients were included and majority of them was female
(73%) and white (62%). A 7-factor (category) structure was noticeable in the corre-
lations among comorbidity candidates across subgroups. Arrhythmias, heart fail-
ure, and ischemic heart disease formed a heart disease category; asthma and ob-
structive pulmonary disease formed a lung disease category; rheumatoid arthritis,
osteoarthritis and nontraumatic joint disorders formed a rheumatic disease cate-
gory, degenerative neurologic disorders and headaches formed a neurologic dis-
ease category, esophageal disorders, gastric and duodenal ulcer formed a gastric
disease category, hepatitis, biliary and liver disorders formed a liver disease cate-
gory, anxiety, depression, affective disorders, schizophrenia, other psychoses
formed a mental disease category. The 7-category model provided best model fit
across subgroups and better predictive performance across different health care
outcomes. Based on a 7-category model, individual comorbidity categories demon-
strated differential impacts for a given outcome. CONCLUSIONS: Instead of one
composite comorbidity score, using comorbidity categories had better risk adjust-
ment and provided insightful information about differential impacts of different
features of comorbidities for further developing efficient comorbidity management
strategies.
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OBJECTIVES: To evaluate the change in the rate of lung function decline before and
after initiation of inhaled corticosteroids (ICS) in children enrolled in the Epidemi-
ologic Study of Cystic Fibrosis (ESCF) through a multivariable mixed-effects piece-
wise linear model. METHODS: The primary outcome measure was the long-term
rate of change in percent predicted forced expiratory volume in 1 second (pp FEV1).
Patients aged 6-17 years who had been enrolled in ESCF for 2 years, when initially
treated with ICS therapy, were selected if they remained on treatment for at least
80% of their visits during the following 2 years. A comparator group included pa-
tients aged 6-17 who did not receive ICS for 4 consecutive years. The index date was
defined as date of ICS initiation (ICS group) or the patient’s even-numbered (8th-
16th) birthday (comparator group). For each patient we estimated the annual rate
of decline in pp FEV1 before and after index using a mixed-effects piecewise linear
model adjusted for age, gender, pulmonary exacerbations, routine therapies, and
nutritional supplements. Model results were used to draw comparisons within and
between study groups. RESULTS: Before initiation of ICS, mean FEV1 decline was
-1.52 pp/year (95% CI: -1.96, -1.08 pp/year). After initiation of ICS therapy, mean
FEV1 decline was -0.44 pp/year (95% CI: -0.85, -0.03 pp/year), which was a significant
change (p0.002). In contrast to our observations in the ICS group, patients in the
comparator group had a mean FEV1 decline of -1.01 pp/year (95% CI: -1.27, -0.75
pp/year) before index, which marginally worsened (p0.046) after index to -1.44
pp/year (95% CI: -1.70 to -1.19 pp/year). CONCLUSIONS: Initiation of ICS was asso-
ciated with a significantly slower subsequent rate of FEV1 decline in children with
cystic fibrosis. Mixed-effects piecewise linear models are valuable for analyzing
observational studies by demonstrating changes in key disease measures corre-
sponding to the times of interventions.
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